2. UroToday Home
  3. Video Lectures

Bladder Cancer Videos

Bladder Burden Survey Findings on Patient Trust, Unspoken Struggles, and Mental Health in Bladder Cancer - Ashish Kamat
CORE-008 Cohort CX: Early Results of Cretostimogene plus Gemcitabine in BCG-Unresponsive and BCG-Exposed NMIBC - Trinity Bivalacqua
CORE-008 CX Early Efficacy and Tolerability Data - Aaron Berger
Findings from the Bladder Burden Survey: Patient Perspectives on Communication, Trust, and Quality of Life in Bladder Cancer - Meri-Margaret Deoudes
Non-Surgical Management of Non-Muscle Invasive Bladder Cancer: Surveillance, Chemoablation, and Office-Based Approaches - Katie Murray
Randomized Trial of Blue Light Versus White Light TURBT with Urinary Tumor DNA Testing - Armine Smith & Meghan McNamara
First-Line Therapy Determines Bladder Preservation in High-Grade NMIBC - Peter Black
Real-World Use of a Urinary Biomarker in a Large Integrated Health System - Christopher Filson
Real-World Claims Analysis of Blue-Light Cystoscopy in NMIBC – Mark Tyson
JCOG1019 Trial: Active Surveillance Versus BCG for T1 Bladder Cancer with Negative Second TUR - Hiroshi Kitamura
Intravesical Mitomycin Hydrogel: Patient-Reported Outcomes Data from OPTIMA II, ATLAS, and ENVISION - Charles Peyton
First-in-Human Trial of a Robotic System for Transurethral Bladder Tumor Resection - Jeremy Teoh
AUA 2026 Bladder Cancer Presentations: EG70, POTOMAC, and En-bloc Resection - Patrick Hensley
AUA 2026 Preview: Perioperative EV/Pembro, ctDNA, and Bladder Preservation - Petros Grivas
AUA 2026 Bladder Cancer Program: Focus on BCG-Naive Intensification Trials - Bogdana Schmidt
BOND-003 Cohort P Examines Gene Therapy for Papillary-Only BCG-Unresponsive Bladder Cancer - Vikram Narayan
Response-Guided Strategy Investigates Omission of Repeat TUR in High-Risk NMIBC - Roberto Contieri
Surgical Management of NMIBC: Comparing En Bloc to Standard Resection Techniques - Jeremy Teoh
Evaluating the Case Against Combining Immune Checkpoint Inhibitors with BCG in Non-Muscle-Invasive Bladder Cancer - Félix Guerrero-Ramos
Prospective Study Investigates ctDNA as an Adjunct to Endoscopic Evaluation Before Cystectomy - Matthew Zibelman
Early Access Program for Cretostimogene Opens Enrollment in BCG-Unresponsive Bladder Cancer - Sarah Psutka
BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams
Managing Radiation Toxicity After Trimodal Therapy for Bladder Cancer - Antoine Van Der Heijden & Neha Vapiwala
CORE-008 Cohort B Evaluates Cretostimogene in BCG-Exposed Non-Muscle Invasive Bladder Cancer - Trinity Bivalacqua
Translational Insights for Cretostimogene Grenadenorepvec for BCG-Naïve Bladder Cancer - Trinity Bivalacqua
Multidisciplinary Teams to Address Quality and Documentation of Bladder Tumor Resection - Patrick Hensley
Cystoscopy vs Urinary Markers: A Debate on Bladder Cancer Surveillance Strategies - Jeremy Teoh & Laura Mertens
CORE-008 Cohort A: Evaluates Cretostimogene in BCG‑Naive High‑Risk NMIBC - Shreyas Joshi
BOND-003 Cohort C: Durability of Responses Examined with Cretostimogene in BCG-Unresponsive Bladder Cancer - Shreyas Joshi
BOND-003 Cohort C: Cystectomy Outcomes Following Cretostimogene in BCG-Unresponsive NMIBC - Gary Steinberg
Phase III Trial Compares BCG Strains and Priming in Non-Muscle-Invasive Bladder Cancer - Robert Svatek
Individual Patient Data Analysis Explores Benefit of Adding Immunotherapy to BCG in Bladder Cancer - Ashish Kamat
SWOG 2427 Tests Immunotherapy Plus Radiation After Neoadjuvant Therapy for Bladder Cancer - Leslie Ballas
SURE-02 Trial Investigates Sacituzumab Plus Pembrolizumab in Bladder Preservation Approach - Andrea Necchi
Biomarker-Based Classification Evaluated for Predicting Progression in High-Risk NMIBC - Joep de Jong
Patient-Reported Outcomes in NMIBC Trials: A 30-Year Analysis of Incorporation Trends - Patrick Hensley
MTAP Loss and Key Alteration Detection via Liquid Biopsy Explored in Bladder Cancer - Chiara Mercinelli
BCAN Unveils Patient-Centered Survey on Emotional and Financial Impacts of Bladder Cancer - Meri-Margaret Deoudes
Revisiting Radiation for Non-Muscle-Invasive Bladder Cancer - Ananya Choudhury
ENVISION Trial Analysis: Reverse Thermal Gel with Mitomycin Outcomes by EORTC Risk Group – William Huang
RESECT Study Investigates Impact of Observation and Feedback on Surgeon Performance - Kevin Gallagher & Veeru Kasivisvanathan
AUC3 Multidisciplinary Consensus Conference Addresses Nuanced Clinical Scenarios in Urologic Cancers - Rana McKay
Developing a Patient-Centered Decision Aid for Urinary Diversion Choices in Bladder Cancer - Divya Ajay
Exploring KDM6A as a Clinically Actionable Biomarker in Bladder Cancer - Sangeeta Goswami
A Multi-Center Study Examines Maintenance Schedules for Intermediate-Risk NMIBC - Roberto Contieri
Systematic Review of Cure Definitions in Early Bladder Cancer - Félix Guerrero-Ramos
AI Model PROGRxN-BCa Tested in Predicting Bladder Cancer Progression - Girish Kulkarni
DRIFT: A Floating Device for Intravesical Gemcitabine-Docetaxel Delivery - James Byrne
Confronting the Persistent Gap Between Training and Leadership for Women in Healthcare - Aparna Kamat & Shilpa Gupta
JSUO and IBCG Collaborate on a Global Standard for TURBT Surgical Checklists - Rikiya Taoka & Mikio Sugimoto
The EMBRACE Trial: An Enhanced Recovery After Surgery Pathway for Transurethral Resection of Bladder Tumors - Michelle Higgins & Max Kates
ASCO GU 2026 Preview: Trials in Bladder and Upper Tract Cancer - Petros Grivas
Examining Delays in the Diagnostic Journey for Patients with Bladder Cancer - Amanda Myers
Evaluating an Integrated Electronic Health Record Pathway for Non-Muscle Invasive Bladder Cancer Care - Fed Ghali
Assessing the Role of Image Quality in VI-RADS for Bladder Cancer Staging - Jelle Barentsz
Analysis of Neoadjuvant Chemotherapy and Survival in Localized Bladder Cancer - Mattia Longoni
Evaluating a Mesh-Based Strategy to Prevent Hernias After Bladder Removal Surgery - Timothy Donahue
Predicting Pelvic Recurrence in Bladder Cancer: A Five-Factor Risk Score - Vidit Sharma
Mexican Bladder Cancer Guidelines Adapt Global Standards to Local Realities and Access - Arturo Mendoza-Valdés
Urine Tumor DNA as a Biomarker for High-Risk Bladder Cancer Recurrence and Guidance - Roger Li
Navigating Treatment Options and Trial Designs for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Vignesh Packiam
CISTO Study: Patient Preferences Drive Bladder Cancer Treatment Choice, Shaping Quality of Life Outcomes - Angela Smith
SUO 2025 Session Highlights: Refined Hematuria Guidelines and Expanding Bladder Cancer Trial Landscape - Woodson Smelser
The Clinical Application of Circulating Tumor DNA in Bladder Cancer Prognosis and Surveillance - Nirmish Singla
Challenges and Management Strategies for BCG-Unresponsive Bladder Cancer - Frances Martin & Patrick Hensley
ALBAN Trial Analysis: Evaluating Atezolizumab Addition to BCG Therapy in High-Risk, Non-Muscle-Invasive Bladder - Morgan Rouprêt
IBCG Task Force Plan to Develop Patient-Reported Outcome Tool for Bladder Cancer - Sarah Psutka
Blue Light Cystoscopy Outcomes and Cost Analysis from the BRAVO Study - Ali Nasrallah
Subgroup Findings from CREST Trial in High-Risk Bladder Cancer - Gary Steinberg
Integrating Complementary Medicine in Bladder Cancer Care - Sarah Psutka
Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria De Santis
Predictive Biomarkers and Liquid Biopsies in Bladder Cancer - David McConkey
Phase 2 Formula-01 Study Evaluates DV Combined With BCG for HER2-High NMIBC - Xingliang Tan
IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li
Enfortumab Vedotin Plus Pembrolizumab FDA-Approved for Cisplatin-Ineligible MIBC - Matthew Galsky
Identifying an Aggressive Subgroup in Low-Grade Bladder Cancer with a Molecular Classifier - Ewan Gibb
Analysis of Three Trials Evaluating BCG Plus Checkpoint Inhibitors in Bladder Cancer - Peter Black
Phase II SURF302 Study Evaluating Oral FGFR3 Inhibitor Dabogratinib - Gautam Jayram
Biomarker Analysis from the SunRISe-1 Trial in BCG-Unresponsive CIS - Félix Guerrero-Ramos
Shifting From TURBT to Chemoablation in Low-Grade Intermediate-Risk NMIBC - Max Kates
SUO 2025 Preview: Bladder Cancer Data from BCG-Unresponsive to Metastatic Disease - Patrick Hensley
Moving Beyond TURBT: Durable LG-IR NMIBC Control with Primary Chemoablation - Sandip Prasad
OPTIMA II Five-Year Data: Mitomycin Chemoablation Provides Durable Response in LG-IR-NMIBC - Neal Shore
CISTO Trial Examines One-Year Survival Between Bladder Removal and Sparing - John Gore
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies - Benjamin Maughan
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi
Survival Gap in Latin American Cancer Care: Public vs Private Systems - Fernando Maluf
Shifting from Surgery to Chemoablation for Low-Grade Bladder Cancer Treatment - Katie Murray
Cost-Effectiveness of Bladder Cancer Treatments Varies by Patient Scenario and Preference - Amanda Myers
Analysis of MRI Use in the Diagnostic Pathway for Bladder Cancer - Nicholas James
Evaluating Chemotherapy De-Escalation in First-Line Urothelial Carcinoma: DISCUS Trial - Enrique Grande
Examining the Workflow of AI Tools for Tissue Analysis in Bladder Cancer - Donna Hansel & Hikmat Al-Ahmadie
Limitations of Urine-Based Biomarkers for Replacing Cystoscopy in Hematuria - Wei Shen Tan
Adjuvant Radiotherapy Evaluated for High-Risk Bladder Cancer After Cystectomy - Vedang Murthy
Assessing Baseline Bladder Function for Patients Considering Trimodal Therapy - Comron Hassanzadeh
Assessment of Urine-Based Tests and Adjuncts in Bladder Cancer Guidelines - Laura Bukavina
International Initiative to Define and Quantify Local Bladder Side Effects - Patrick Hensley
Examining Guidelines on Radiotherapy for Bladder Cancer with Carcinoma In Situ - Constance Huck
SunRISe-1 Trial of the TAR-200 Gemcitabine Delivery System - Siamak Daneshmand
Financial Toxicity and Economic Burden for Bladder Cancer Patients - Parminder Singh
Strategies for Integrating Patient-Reported Outcomes in Urologic Oncology Research - Kelly Bree
Non-Invasive Monitoring Options for Bladder Cancer Patients - Kristen Scarpato
Multiplex Urine Protein Assay Performance in a Real-World Multi-Center Clinical Setting - Hideki Furuya
Power and Replication Rates in Randomized Cancer Trials - Pavlos Msaouel
ZUSDURI™ FDA Approved for Low-Grade Intermediate-Risk Bladder Cancer - Mark Schoenberg
Analysis of Four-Tier Hybrid Grading System for Ta Non-Muscle-Invasive Bladder Cancer - Roberto Contieri
Guidelines for High-Risk Non-Muscle Invasive Bladder Cancer Treatment Options - Neal Shore
Technology-Driven Innovation in Bladder Cancer: Surgery, Surveillance, and Beyond – Saum Ghodoussipour
Global Bladder Cancer Advocacy Group Establishes Scientific Advisory Board - Alex Filicevas
Comparison of Radical Cystectomy and Bladder-Sparing Therapy for Non-Urothelial Histologies - Mattia Longoni
Economic Evaluation of Bladder Preservation vs. Radical Cystectomy - Daniel Joyce
Artificial Intelligence and Machine Learning in Bladder Cancer Pathology and Clinical Decision-Making - Hikmat Al-Ahmadie & Alexandre Zlotta
Management Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer - Roberto Contieri
Study on Dedicated Patient Navigation for Female Bladder Cancer Patients - Bryn Launer
ABLE-22 Trial: Comparing Combination Therapies for BCG-Unresponsive Bladder Cancer - Siamak Daneshmand
An Artificial Intelligence Predictive Biomarker for Response to BCG vs Gemcitabine-Docetaxel for High Grade NMIBC - Vignesh Packiam
Treatment Dilemmas for BCG-Unresponsive Bladder Cancer in Canada and Beyond - Wassim Kassouf
Computational Histology AI's Potential in Refining NMIBC Prognostication - Bryn Launer
Optimizing Patient Selection and Treatment Timing for Emerging Intravesical Therapies - Vignesh Packiam
The State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer - Leslie Ballas, Parminder Singh & Mark Tyson
Low-Grade Ta Bladder Tumors Show Unexpected Metastatic Potential in Long-Term Study - Alexandre Zlotta
Expanding Treatment Options: FDA Approval of Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk NMIBC - Sandip Prasad
Blue Light Cystoscopy Detects Hidden Bladder Cancer After Induction Therapy - Vignesh Packiam
Event-Free Survival and Emerging Immunotherapy Approaches in High-Risk NMIBC - Neal Shore
SSANTROP Trial: Evaluating Sasanlimab Plus Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joaquim Bellmunt
Cretostimogene Expanded Access Program Provides Alternative for BCG-Unresponsive Bladder Cancer Patients - Wassim Kassouf
Tumor Characteristics and Response Patterns in the ENVISION UGN-102 Trial - John Sfakianos
Computational Histology AI Guides Treatment Selection for Bladder Cancer Patients - Vignesh Packiam
Radiation vs Systemic Therapy for Isolated Pelvic Recurrence After Cystectomy - Andrea Necchi & Comron Hassanzadeh
AUA 2025 Highlights: Advances in Non-Muscle Invasive Bladder Cancer - Patrick Hensley & Janet Kukreja
Examining Under-Staging in BCG-Unresponsive Bladder Cancer Patients Undergoing Radical Cystectomy - Katharina Oberneder
SunRISe-1 Trial: Bladder-Sparing Results for BCG-Unresponsive Disease - Felix Guerrero-Ramos
Efficacy of TAR-200 in Non-Muscle Invasive Bladder Cancer: 1-Year Outcomes - Joseph Jacob
ADVANCED-2 Trial: TARA-002 in BCG-Naive High-Risk NMIBC - Brian Mazzarella
PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Max Kates
BCG-Unresponsive Bladder CIS: Real-World Data Reveals High Recurrence and Treatment Gaps - Stephen Williams
MoonRISe-1 Trial: Evaluating TAR-210 for FGFR-Altered Intermediate-Risk NMIBC - Roger Li
Multicenter European Trial Investigates Gem/Doce for Non-Muscle Invasive Bladder Cancer - Pietro Scilipoti
Pre-Cystectomy ctDNA Levels and Metastatic Recurrence in Bladder Cancer Patients - Reuben Ben-David
International Validation of AI Tool for Stratifying Bladder Cancer Progression Risk - Jethro Kwong
AI Risk Calculator Outperforms EAU Models for Bladder Cancer Prognosis - Alexandre Zlotta
Active Surveillance vs TURBT for Low-Grade Ta Bladder Cancer - Morgan Rouprêt & Laura Bukavina
Practice-Changing Advances in Urothelial Cancer: Highlights Across Disease States - Alice Yu
SunRISe-1 Trial Shows TAR-200 Efficacy in BCG-Unresponsive Bladder Cancer - Felix Guerrero-Ramos
CISTO Study: Comparing Cystectomy vs. Bladder-Sparing Therapy for Recurrent NMIBC - John Gore
Real-World Implementation of Biomarkers for Microhematuria Workup - Ronald Loo & Christopher Filson
AUA Microhematuria Guidelines 2025 - Daniel Barocas
Real-World Data Improves NMIBC Risk Assessment with Blue Light Technology - Siamak Daneshmand & Boris Gershman
Platform Reduces Unnecessary Cystoscopies for Hematuria Patients - John Sfakianos
Checkpoint Inhibition in BCG-Naive NMIBC: Mechanisms and Emerging Evidence - Matthew Galsky
CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder Cancer - Trinity Bivalacqua
CORE-008 Cohort B: Cretostimogene for BCG-Exposed NMIBC – Trial Activation & Clinical Goals - Trinity Bivalacqua
BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark Tyson
CUT-less Trial Aims to Eliminate Secondary TURBT in Non-Muscle Invasive Bladder Cancer - Francesco Del Giudice
Evaluating Risk Stratification Models for Blue Light Cystoscopy in Bladder Cancer - Sia Daneshmand & Boris Gershman
Streamlining Intravesical Therapy: Practical Insights for BCG-Unresponsive NMIBC - Patrick Hensley
Biomarkers for Gemcitabine Docetaxel in Non-Muscle Invasive Bladder Cancer - Vignesh Packiam
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines - Jay D. Raman & Yair Lotan
Refining Risk in NMIBC: Intermediate Stratification, TURBT Quality, and Emerging Options - Katie Murray
Predicting BCG Therapy Response in High-Grade Non-Muscle Invasive Bladder Cancer - Weranja Ranasinghe
Managing BCG-Unresponsive Bladder Cancer: Balancing Bladder Preservation and Cystectomy - Paolo Gontero & Maria Carmen Mir
Prehabilitation in Cancer Care: Personalized Exercise Programs for Better Outcomes - Sarah Psutka
Gender Disparities in Bladder Cancer Care and Treatment Considerations for Women - Jeannie Hoffman-Censits & Armine Smith
Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer - Marco Moschini
Cretostimogene Grenadenorepvec Complete Response in BOND-003 Cohort C - Trinity Bivalacqua
Evolving Treatment Landscape for Non-Muscle Invasive Bladder Cancer Beyond BCG - Bogdana Schmidt
LEGEND Trial: EG-70 in BCG-Refractory Non-Muscle Invasive Bladder Cancer - John Taylor
ENVISION Trial Evaluates UGN-102 for Recurrent Low-Grade NMIBC Bladder Cancer - Sandip Prasad
Genomic Landscape of Non-Muscle Invasive Bladder Cancer from UROMOL Consortium - Lars Dyrskjøt
Primary Chemo Ablation with UGN-102 for Recurrent Low Grade Bladder Cancer in the ENVISION Trial - Sandip Prasad
Detecting ctDNA in High-Risk Non-Muscle Invasive Bladder Cancer - Dan Isaac
Understanding ctDNA Technology Applications for Cancer Detection and Characterization - Alexander Wyatt
Global Disparities in Bladder Cancer Clinical Trial Availability Across Income Classifications - Koral Shah
Immune Infiltration Gene Signatures Predict Response to Gemcitabine Docetaxel vs BCG in Bladder Cancer - Michael O'Donnell
Circulating and Urinary Tumor DNA in Bladder Cancer Treatment and Surveillance - Alan Tan
Cretostimogene Grenadenorepvec Expanded Access Program for BCG-Unresponsive Bladder Cancer - Sarah Psutka
Germline Testing for Risk Stratification in Low-Grade Bladder Cancer on Active Surveillance - Roberto Contieri
Bladder Cancer Risk Stratification Using Non-Coding RNA - Yair Lotan
Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam
Comparing Industry-Sponsored and Investigator-Initiated Trials in Genitourinary Oncology - Srikala Sridhar
Intravesical Antibody-Drug Conjugates for Bladder Cancer - Di Maria Jiang
Gender Differences in Bladder Cancer Diagnosis, Treatment, and Patient Care - Elizabeth Guancial
Advances in Non-Muscle Invasive Bladder Cancer Treatment Options - Bogdana Schmidt
Global BCG Shortage Impacts Treatment for High-Risk Bladder Cancer Patients - Jens Bedke
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
Micropapillary Histology in Bladder Cancer: A Retrospective Survival Analysis - Muhammad Alkazemi & Hikmat Al-Ahmadie
Dual Immune Activation with EG-70 Targets Non-Muscle Invasive Bladder Cancer - Vikram Narayan
VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study - Beyond the Abstract
What Everyone’s Talking About: Highlights from SUO 2024 - Amy Luckenbaugh
SunRISe-5 Trial Tests TAR-200 for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Sima Porten
Bladder-Sparing Therapy vs Upfront Cystectomy: Long-Term Outcomes in BCG-Unresponsive Bladder Cancer - Jacob Taylor
Smoking Cessation as a Precision Cancer Care Intervention in Urologic Oncology - Richard Matulewicz
BCG-Unresponsive Bladder Cancer Study Examines Risks of Bladder-Sparing Therapies for T1 Disease - Yair Lotan
Sequential Gemcitabine and Docetaxel Examined in BCG-Unresponsive Bladder Cancer Patients - Yair Lotan
FGFR3 Inhibition in Urothelial Cancer Advances with Erdafitinib and TAR-210 Trials - Gopa Iyer
Cost-Effectiveness of Bladder-Sparing Treatments vs. Radical Cystectomy in BCG-Unresponsive NMIBC - David D’Andrea
Preventing and Managing Complications of Radical Cystectomy - Hadley Wyre
CISTO Trial Highlights Strategies to Boost Enrollment in Large Clinical Studies - Krupa Nathan & Angela Smith
Phase II Trial Explores Gemcitabine Plus BCG for BCG-Exposed Bladder Cancer - Eugene Pietzak & Gal Wald
Navigating Young-Onset Bladder Cancer - From Genomics to Survivor Perspectives - Ashish Kamat
The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist - Cheryl Lee
Moving Beyond Single Arm Trials in BCG Unresponsive Cancer Care - Joshua Meeks
Safety and Tolerability of TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer in SUNRISE-1 - Siamak Daneshmand
High Risk Bladder Cancer Treatment Outcomes After Additional BCG - Amanda Myers
Sexual Dysfunction After Radical Cystectomy - Trinity Bivalacqua
CORE-008 Cohort B Tests Cretostimogene’s Efficacy in High-Risk, Non-BCG-Responsive Disease - Trinity Bivalacqua
CORE-008 Cohort A Tests Oncolytic Immunotherapy in BCG-Naive High-Risk Bladder Cancer - Trinity Bivalacqua
Real-World Treatments Following BCG Induction in Patients with NMIBC: A US Claims Analysis - Amanda Myers
Lessons Learned from Other Cancers that Can be Applied to Bladder Cancer - Petros Grivas
Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka
Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski
Advancing Treatment for BCG-Unresponsive Bladder Cancer - Eugene Pietzak
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson
BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat
BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson
RAIDER Trial: Safety of Tumor-Directed Dose Escalation - Robert Huddart
Gemcitabine and Docetaxel Combination Offers Promising Alternative to BCG in Bladder Cancer Treatment - Sunil Patel & Max Kates
Trimodality Therapy Preserves Bladder in High-Grade T1 Bladder Cancer Patients - Douglas Dahl
Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract
Occupational and Environmental Factors Linked to Bladder Cancer in High-Risk Groups - Sunil Patel
Working Group Addresses Excellence in Community Bladder Cancer Care Delivery - Janet Kukreja
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka
LEGEND Trial Investigates EG-70 in Bladder Cancer Patients - Gautier Marcq
JCOG1019 Trial Examines Watchful Waiting vs BCG for High-Grade T1 Bladder Cancer - Hiroshi Kitamura
Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
Genetic Profiles in Early vs. Late Stage Urothelial Cancer - Dag Stormoen
Harnessing Artificial Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment - David McConkey
Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
Stratification Tool Identifies High-Risk Patients Within Heterogeneous Bladder Cancer Group - Francesco Soria
Novel Therapies for Non-Muscle Invasive Bladder Cancer: Expert Review - Felix Guerrero-Ramos
Urban vs Rural Bladder Cancer Mortality: 20-Year Trend Analysis - Jason Brown
ctDNA in Non-Muscle Invasive Bladder Cancer: Screening & Prognosis - Saum Ghodoussipour
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
Novel CD40 Antibody Treatment for BCG-Unresponsive Bladder Cancer - Bernard Bochner
Robotic vs. Open Radical Cystectomy: 3-Year RCT Results Revealed - Giuseppe Simone
Advancing Female Bladder Cancer Care: Insights from AUA's First Specialized Course - Armine Smith
Orion Study Evaluates Paclitaxel Conjugate for BCG-Unresponsive Cancer - Sunil Patel
Patient Burdens and Openness to In-Home Intravesical Therapy for Bladder Cancer - Timothy Lyon & Amanda Myers
Optimizing Next-Generation Sequencing in Urothelial Cancer: Expert Consensus Recommendations - Andrea Necchi
MoonRISe-1: Evaluating TAR-210 for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer - Roger Li
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
Adequate BCG Therapy for Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Analysis - José Daniel Subiela Henriquez
Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan
Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing
KEYNOTE-676 Cohort A: Pembrolizumab + BCG for Previously BCG-Treated NMIBC - Neal Shore
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
SSANTROP Trial: Evaluating Sacituzumab Govitecan and Sasanlimab for BCG-Unresponsive Bladder Cancer - Oscar Rodriguez-Faba
Exploring the Complexities of Bladder Cancer Surveillance: Cytology, UroVysion, and Beyond - Komal Pohar & Kelly Bree
The Evolving Role of Radical Cystectomy in the Era of Bladder-Sparing Therapies - Sima Porten & Roger Li
Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer - Michael Cookson & Paolo Gontero
To TURBT or Not to TURBT? Evaluating Treatment Options for Recurrent Low-Grade, Intermediate-Risk Bladder Tumors - Sarah Psutka & Param Mariappan
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
Defining Standard and Extended Pelvic Lymphadenectomy in Bladder Cancer Surgery - Seth Lerner & Siamak Daneshmand
AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients - Yair Lotan
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson
Navigating the Expanding Landscape of BCG-Unresponsive NMIBC Treatment Options - Mark Tyson
VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams
SunRISe-3 Trial: TAR-200 with or without Cetrelimab vs. BCG for BCG-Naive High-Risk NMIBC - Sam Chang
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson
Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study - Siamak Daneshmand
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein
How Long is Recovery After TURBT? Patient-Reported Outcomes Provide Answers - Marshall Strother
Clearing the Smoke: Underreporting of Smoking Status in Bladder Cancer Clinical Trials - Hannah Kay & Marc Bjurlin
AIM High: Epigenetic Modulation and Immune Stimulation in Bladder Cancer - Elizabeth Koehne
Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam
Guidelines Aim to Harmonize and Optimize Urothelial Carcinoma Clinical Trials - Ashish Kamat and Matthew Galsky
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore
Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes - Kyle Richards
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis - James Ferguson
Plasmacytoid Variant Bladder Cancer: Aggressive Disease Requiring Multimodal Therapy - Akshay Sood
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity - Roger Li
Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li
ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky
Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin
The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams
BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks
Treatment Options Expand for BCG Unresponsive Bladder Cancer - Mark Tyson
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
The Microbiome's Impact on the Immunotherapy of Genitourinary Cancers - Sumanta Kumar Pal
Bladder Cancer: En Bloc Resection Technique Shows Promise - David D'Andrea
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? - Amanda Myers
Chinese Trial Blue Light Cystoscopy Superior for Bladder Cancer Detection - Hongxian Zhang
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson
Exploring Promising Therapies and Genomic Insights in Bladder Cancer Research - Laura Bukavina
Bladder Cancer Patients Experience High Burden From Current Intravesical Therapy Model - Amanda Myers
Phase 2 Trial: Chemotherapy Plus Immunotherapy Facilitates Bladder Sparing in Muscle-Invasive Bladder Cancer - Matthew Galsky
Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen
Exploring Bladder Cancer Innovations: A Deep Dive into ESMO 2023 - Morgan Rouprêt
Operationalizing Blue Light in Your Practice - Gautam Jayram
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek
Novel Gene Therapy Shows Efficacy and Tolerable Safety Profile for Patients with Treatment-Resistant Bladder Cancer - Trinity Bivalacqua
For Bladder Cancer Patients, New Hope From Immunotherapy Innovations from ESMO 2023 - Petros Grivas
Supportive Care in Bladder Cancer: A Deep Dive into Global Patient Needs and the Role of Healthcare Professionals - Bente Jensen & Alex Filicevas
Bladder Cancer's Impact on Daily Life and Employment: A Global Perspective - Lydia Makaroff & Lori Funk-Cirefice
Quality of Life in Bladder Cancer: A Comparative Study on Cystectomy vs. Bladder Preservation - Vedang Murthy
The Global Bladder Cancer Survey: A Strategic Analysis of Diagnosis and Care - Stephanie Demkiw & Lydia Makaroff
Global Insights into Bladder Cancer Care: A Comprehensive Survey by the World Bladder Cancer Patient Coalition - Patrick Hensley & Lydia Makaroff
Advancing Bladder Cancer Surveillance: The Impact of Flexible Blue Light Cystoscopy from the Nordic Registry - Karsten Zieger
New Research Sheds Light on Alternative Treatments for Node-Positive Bladder Cancer - Martin Swinton
A New Approach to Bladder Cancer: The ATLAS Trial's Exploration of UGN-102 and TURBT, Journal Club - Rashid Sayyid & Zachary Klaassen
A Didactic Lecture on Variant Histology for Urothelial Carcinoma - Charles Guo
Comprehensive Geriatric Assessments in Urologic Cancer Care: Identifying Modifiable Risk Factors for Personalized Treatment - Sarah Psutka
Device-Assisted Therapies for Bladder Cancer: History, Mechanisms, and Clinical Trials - Wei Shen Tan
2023 BCAN Research Innovation Award - Christopher Garris
A Mechanism of Tumor Suppression: Unveiling Transcription-Translation Conflict - Andrew Hsieh
Tumour Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study - Kevin Gallagher
Radical Cystectomy vs. Trimodal Therapy: Outcomes in Bladder Cancer - Alexandre Zlotta
Extended Node Dissection in Bladder Cancer: SWOG S1011 Trial Insights - Seth Lerner
Diversity and Excellence: The Key Criteria in BCAN's Travel Fellowship Selection Process - Max Kates & Petros Grivas
Mental Health Illness in Patients with Non-Muscle Invasive Bladder Cancer. Does BCG Play a Role? - Valentina Grajales
Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer - Joshua Meeks
Reflecting on the 25-Year History of the International Bladder Cancer Network - Peter Goebell
NMIBC Molecular Subtypes Predict Differential Response to Intravesical BCG - Tahlita C. M. Zuiverloon
Unlocking New Frontiers in Bladder Cancer Treatment with Chemo Ablation and Emerging Technologies - Jørgen Bjerggaard Jensen
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
The Potential Influence of Circulating Tumor DNA in Treatment Decisions for Bladder Cancer - Petros Grivas
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
Exploring Acupuncture's Potential to Mitigate BCG Therapy Side Effects: A Phase I/II Trial - Sarah Psutka
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes - Gottfrid Sjodahl & Fredrik Liedberg
Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer - Timothy Clinton
Improving Bladder Cancer Treatment: An Insight into Vanderbilt's Innovative BCG Clinic - Meredith Donahue & Tara Cumming
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage - Brian Chun
Unveiling the Promising Role of FAP PET Imaging in Accurate Bladder Cancer Staging - Domenique Escobar
Novel Models for Bladder Cancer Progression and Drug Development - John Taylor III
When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer - Roberto Contieri
Agent Orange and Bladder Cancer: Insights from a Study on 25 Million Veterans - Stephen Williams
Exploring Tumor Biomarkers in Urothelial Carcinoma: Insights and Advancements in Bladder Cancer Research - Chad Ritch
Optimizing Care of Bladder Cancer in Women - Katie Murray
Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li
Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz
The "Get Moving Trial" Home-based Pre and Rehabilitation Intervention for Muscle-invasive Bladder Cancer, BCAN Translational Clinical Trial Award - Sarah Psutka
Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial - Michiel Van der Heijden
Developing Centers of Excellence for Treatment of Major Urological Cancers in Australia - Manish Patel
Gene Expression and Molecular Subtyping in GU Cancers Presentation - Ewan Gibb
The SunRISe-4 Trial: A Critical Look at Immunotherapy in Bladder Cancer - Sarah Psutka
Fueling Wellness with Flavor for Cancer Patients: The Wellness Principles - Gary Deng
A Glimpse into the Future of Bladder Cancer Treatment and Innovative Approaches to Enhanced Patient Care - John Sfakianos
Exploring the Prognostic and Predictive Value of ctDNA with Signatera - Adam ElNaggar
EAU Guidelines on Thromboprophylaxis in Urological Surgery - Kari Tikkinen
Risk of Progression in NIMBC Patients Treated with BCG Overestimated by Updated European Association of Urology (EAU) Prognostic Factor Risk Groups - Niyati Lobo
From Science to Clinical Utility: Cxbladder Monitor - Bladder Cancer Surveillance for Patients with Urothelial Carcinoma - Tamer Aboushwareb, Neal Shore & Josh Meeks
From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria - Tamer Aboushwareb, Neal Shore & Josh Meeks
Using Artificial Intelligence (AI) to Identify and Diagnose Bladder Cancer - Hikmat Al-Ahmadie & Olivier Elemento
MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James
Unlocking the Potential of Immunohistochemical Panels in Bladder Cancer Treatment - Patrick Hensley
Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
Women in Urologic Oncology - Anne K. Schuckman
Bladder Cancer Highlights - Stephen Williams
Bladder Cancer in the Older Adult Population: Special Considerations - Tullika Garg
Highlighting 25 Years of the International Bladder Cancer Network (IBCN) - Barton Grossman
The Controversy Over Radical Cystectomy for N1 and N2 Bladder Cancer: Experts Weigh In - Brant Inman & Yair Lotan
Gender Differences in Bladder Cancer - Lauren Cooley
Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
Microbiome Research in Bladder Cancer - Laura Bukavina
Realities of Bladder Cancer In Women - Sima Porten, Kristen Scarpato, Svetlana Avulova & Anne Schuckman
The Critical Role of Nursing in Bladder Cancer Diagnostics and Treatment - Shievon Smith & Jacqueline Duncan
Busting Common Myths Regarding Bladder Preservation for Muscle Invasive Bladder Cancer - Nick James & Ananya Choudhury
The CABEM Project and the Power of Teamwork: How Multidisciplinary Collaboration Improved Bladder Cancer Outcomes in Brazil - Fernando Korkes
RETAIN Trial: A New Hope for Avoiding Cystectomy in Bladder Cancer - Phillip Abbosh
Urethral Recurrence after Radical Cystectomy for Bladder Cancer - Ekaterina Laukhtina
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
'BCG-Exposed' Definition Aims to Improve Bladder Cancer Care - Peter Black
Comparative Effectiveness of Radical Cystectomy and Trimodality Therapy for Muscle-Invasive Bladder Cancer – Boris Gershman
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumor - Sia Daneshmand
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Mucosal Differences in The Bladder - Molly Ingersoll
Translational Research in Bladder Cancer, A BCAN Young Investigator - Phillip Abbosh
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
From Athens to Seattle: A Global Conversation on Urologic Care and the Société Internationale d'Urologie - Petros Grivas & Athanasios Papatsoris
How Tech Can Minimize Immune-Related Toxicities in Cancer Patients - Pavlos Msaouel
Urologists, You’ll Never Walk Alone! - Gianluca Giannarini
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
New Subtype Discovery May Offer Better Treatment Options for Bladder Cancer Therapy - Dan Theodorescu
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams
ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen
Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas
Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
The Role of Radiology and Radiomics in Staging & Risk Stratification of NMIBC - Manjiri Dighe
Germline and Somatic Interactions in Bladder Cancer - Bishoy Faltas
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar
A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg
Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan
Addressing the BCG Shortage: New Strains and Alternative Treatment Options on the Horizon for Bladder Cancer - Janet Kukreja
Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder - Stephen Boorjian & Kevin Wymer
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer - Lars Dyrskjøt
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2020 Update - Marek Babjuk
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
The Role of the PD-L1 Checkpoint in BCG Resistance - Max Kates
Vicineum for High-Risk Non-Muscle-Invasive BCG Unresponsive Bladder Cancer - Rian J. Dickstein
Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar
A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar
T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar
Clinically Node Positive Bladder Cancer and The Timing of Surgery - Neema Navai
The Management of Bladder Cancer During Pregnancy - Makarand Khochikar
Radical Cystectomy and The Importance of Oncological Concepts in Surgical Approach - Rafael Sanchez Salas
T2 N0 M0 Muscle-invasive Bladder Cancer Patient Case - Makarand Khochikar
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
Urinary Diversion in Women Following Radical Cystectomy - Renu Eapen
Blue Light Cystoscopy with Cysview®: Tips and Tricks - Anne Schuckman
The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan
AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten
Macro and Microeconomics of Blue Light Cystoscopy with CYSVIEW® in Non-Muscle Invasive Bladder Cancer - Stephen Williams
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf
Role of Blue Light Cystoscopy in Bladder Cancer Management - Trinity Bivalacqua
Bladder Preservation Protocols for Muscle-Invasive Urothelial Carcinoma - Arjun Balar
Weathering the Current BCG Shortage Crisis - Michael O’Donnell
Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits
Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen
Research and Clinical Practice Strategies Due to the BCG Shortage - Sam S. Chang
Bladder Cancer Research That Impacts Urology Clinical Practice - Josh Meeks
The Benefits of Early Recovery After Radical Cystectomy (ERAS) Protocols - Sima Porten
The BCG Shortage - What To Do In This Setting - Joshua Meeks
Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Badrinath Konety
Guided Imagery for Urologic Surgery - Sima Porten
Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan
Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams
Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan
Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman
Optimal Surgical Approaches in Cystectomy - Piyush Agarwal
Toxicity Management with Checkpoint Inhibitor Therapy - Thomas Powles
Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer - Stephen B Williams
Improving Outcomes in Bladder Cancer - Arnulf Stenzl
Bladder Cancer in Women - Morgan Roupret
Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles
The Role of the Surgeon in the Treatment of Bladder Cancer - Jens Bedke
Defining BCG-Unresponsive and The Pathway to Clinical Trials in Treating NMIBC - Ashish Kamat
BCG Shortage An Update - Jonathan Rubenstein
What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks
ERAS in Bladder Cancer - Sia Daneshmand
The State of Immunotherapy in Bladder Cancer - Thomas Powles
Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits
The Role of the Surgeon in the Management of Metastatic Bladder Cancer - Brant Inman
BCG Shortage 2019: Managing Through Treatment and Reimbursement Issues - Neal Shore, Ashish Kamat, and Jonathan Rubenstein
2019 BCG Shortage-Perspectives from Josh Meeks
Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten
Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
Patient Reported Outcomes in the Use of Blue Light Cystoscopy in the Surveillance of Bladder Cancer - Angela B. Smith
Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat
Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn
Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat
Keynote-057 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Evan Yu
Is There Still a Role for Chemotherapy in Bladder and Prostate Cancer - Maria De Santis
Immunotherapy in Bladder Cancer - Arjun Balar
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane
Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas
FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas
Update in Immuno-Oncology in Bladder Cancer - Arjun Balar
Journey from Oncologist to Cancer Survivor and Patient Advocate - Burton Needles
Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat
Helping Patients Cope after Major Interventions for Bladder Cancer Therapy
The Changing Landscape in Advanced Bladder Cancer - Tom Keane
Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Enhanced Recovery After Surgery (ERAS) for Radical Cystectomy: History, Rationale and Programmatic Implementation - Thomas Guzzo
Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde
Enhanced Recovery After Surgery (ERAS) Radical Cystectomy and Urinary Diversion- Ashish Kamat